Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges.
Infectious laryngotracheitis (ILT) is a highly contagious acute respiratory disease of chickens caused by infectious laryngotracheitis virus (ILTV). The disease is controlled mainly through biosecurity and vaccination with live attenuated strains of ILTV and vectored vaccines based on turkey herpesvirus (HVT) and fowlpox virus (FPV). The current live attenuated vaccines (chicken embryo origin [CEO] and tissue culture origin [TCO]), although effective, can regain virulence, whereas HVT- and FPV-vectored ILTV vaccines are less efficacious than live attenuated vaccines. Therefore, there is a pressing need to develop safer and more efficacious ILTV vaccines. In the present study, we generated Newcastle disease virus (NDV) recombinants, based on the LaSota vaccine strain, expressing glycoproteins B (gB) and D (gD) of ILTV using reverse genetics technology. These recombinant viruses, rLS/ILTV-gB and rLS/ILTV-gD, were slightly attenuated in vivo yet retained growth dynamics, stability, and virus titers in vitro that were similar to those of the parental LaSota virus. Expression of ILTV gB and gD proteins in the recombinant virus-infected cells was detected by immunofluorescence assay. Vaccination of specific-pathogen-free chickens with these recombinant viruses conferred significant protection against virulent ILTV and velogenic NDV challenges. Immunization of commercial broilers with rLS/ILTV-gB provided a level of protection against clinical disease similar to that provided by the live attenuated commercial vaccines, with no decrease in body weight gains. The results of the study suggested that the rLS/ILTV-gB and -gD viruses are safe, stable, and effective bivalent vaccines that can be mass administered via aerosol or drinking water to large chicken populations.


OBJECTIVE
This paper describes the development and evaluation of novel bivalent vaccines against chicken infectious laryngotracheitis (ILT) and Newcastle disease (ND), two of the most economically important infectious diseases of poultry. The current commercial ILT vaccines are either not safe or less effective. Therefore, there is a pressing need to develop safer and more efficacious ILT vaccines. In the present study, we generated Newcastle disease virus (NDV) recombinants expressing glycoproteins B (gB) and D (gD) of infectious laryngotracheitis virus (ILTV) using reverse genetics technology. These recombinant viruses were safe, stable, and immunogenic and replicated efficiently in birds. Vaccination of chickens with these recombinant viruses conferred complete protection against ILTV and NDV challenge. These novel bivalent vaccines can be mass administered via aerosol or drinking water to large chicken populations at low cost, which will have a direct impact on poultry health, fitness, and performance.
Southeast Poultry Research Laboratory, Agricultural Research Services, U.S. Department of Agriculture, Athens, Georgia, USA.
Wei
W
Zhao
Southeast Poultry Research Laboratory, Agricultural Research Services, U.S. Department of Agriculture, Athens, Georgia, USA.
Stephen
S
Spatz
Southeast Poultry Research Laboratory, Agricultural Research Services, U.S. Department of Agriculture, Athens, Georgia, USA.
Zhenyu
Z
Zhang
Southeast Poultry Research Laboratory, Agricultural Research Services, U.S. Department of Agriculture, Athens, Georgia, USA.
Guoyuan
G
Wen
Poultry Diagnostic and Research Center, Department of Population Health, College of Veterinary Medicine, The University of Georgia, Athens, Georgia, USA.
Maricarmen
M
Garcia
Southeast Poultry Research Laboratory, Agricultural Research Services, U.S. Department of Agriculture, Athens, Georgia, USA.
Laszlo
L
Zsak
Southeast Poultry Research Laboratory, Agricultural Research Services, U.S. Department of Agriculture, Athens, Georgia, USA qingzhong.yu@ars.usda.gov.
Qingzhong
Q
Yu
D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002645:Chickens; D005822:Genetic Vectors; D006566:Herpesviridae Infections / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D009521:Newcastle Disease / Q000473:pathology / Q000517:prevention & control*; D009522:Newcastle disease virus / Q000235:genetics / Q000276:immunology*; D011201:Poultry Diseases / Q000517:prevention & control*; D012720:Severity of Illness Index; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C000591972:glycoprotein B, Gallid herpesvirus 1; C094674:glycoprotein D, Gallid herpesvirus 1